Skip to Content
Merck
CN
  • Pharmacological characteristics of zolpidem-induced catalepsy in the rat.

Pharmacological characteristics of zolpidem-induced catalepsy in the rat.

Neuroscience letters (2013-10-19)
Pawel Mierzejewski, Marcin Kolaczkowski, Natalia Nowak, Agnieszka Korkosz, Anna Scinska, Halina Sienkiewicz-Jarosz, Jerzy Samochowiec, Wojciech Kostowski, Przemyslaw Bienkowski
ABSTRACT

Zolpidem is a non-benzodiazepine hypnotic drug acting preferentially at α1-containing GABAA receptors expressed in various parts of the brain, including the basal ganglia. The aim of the present study was to provide preliminary characteristics of zolpidem-induced catalepsy in Wistar rats. Zolpidem (2.5-10.0mg/kg), but not diazepam and midazolam, produced dose-dependent cataleptic responses in the bar test, which were similar to those produced by a reference antipsychotic drug, haloperidol. Zolpidem-induced catalepsy was abolished by a benzodiazepine site antagonist, flumazenil (5.0mg/kg), D2/3 receptor agonist, quinpirole (1.0mg/kg), and a non-competitive NMDA receptor antagonist, MK-801 (0.1mg/kg), but not by a non-selective opioid receptor antagonist, naltrexone (3.0mg/kg). The present results indicate that systemic injections of zolpidem may produce short-lasting, neuroleptic-like catalepsy in the rat.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(+)-MK-801 hydrogen maleate, powder
Sigma-Aldrich
(−)-Quinpirole hydrochloride, ≥98% (HPLC), solid
Supelco
Naltrexone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®